Rethinking High-Dose Oral Vitamin B12: Improving Patient Safety in Response to Emerging Data

There is emerging evidence indicating that sustained high serum vitamin B12 levels may be associated with increased risks of certain adverse health events (1). Considering these new findings, clinicians who dispense high-dose oral vitamin B12 supplementation—typically 1,000 µg or more daily—may want to regularly monitor their patients' serum B12 levels and consider reducing doses if levels rise above the normal range. Whenever possible, it may be safer to use lower-dose B12 supplementation to avoid unnecessarily high vitamin B12 levels.

Low-dose oral B12 therapy (25–100 µg/day) is often sufficient to correct mild deficiencies and improve nerve function, especially in older adults or those with reduced absorption due to medications such as metformin or proton pump inhibitors. This approach helps patients achieve the benefits of B12 supplementation without reaching excessively high, potentially harmful levels.

At Realm Labs, we have updated our NeuRemedy® product line of benfotiamine and vitamin B12 nutritional products to reflect these important new findings. NeuRemedy® is the gold standard for the nutritional management of nerve dysfunction in the feet and legs. Our formulations enable you to supplement your patients with vitamin B12 while maintaining optimal serum levels, avoiding excessive elevations. This strategy enhances both safety and efficacy in the long-term management of neuropathic symptoms.

We encourage you to review your current B12 supplementation protocols and consider whether a lower-dose approach may better support patient safety in your practice. For more information about NeuRemedy® or to discuss the latest evidence, please contact us.